16887 results about "Treatment effect" patented technology

The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

Disclosed is a system and method of assessing the efficacy of treatment of neurological or psychological disorders. The preferred embodiment uses at least two surface electrodes to acquire EEG signals from the surface of a patient's body, a processor for computing from the EEG signals various features and indices that are representative of the patient's neurological or psychological state. Changes in these parameters may be used to assess the efficacy of treatment and to modify the treatment to optimize the resultant patient state.

A typical treatment system for use with tip embodiments includes an optical energy source, such as, for example, a laser. A set of tips may be interchangeably attached to the treatment system, for example to alter the system parameters and the treatment provided through the individual tips. Embodiments of the present invention include tips with a security chip and / or a memory. A security chip protects the treatment system from use with unauthorized tips, and the memory stores information about the tips and / or the treatment system to enhance the treatment

The present invention relates to compositions or combinations of materials for non-degradable and degradable implantable medical devices with regard to the setup of their signal generating properties and control of their therapeutic effectiveness, as well as to a method for the control of degradation of degradable or partially degradable medical devices composed like this, based on their signal generation, and to a method for supervision of their therapeutic effectiveness and / or the release of therapeutically active ingredients from such devices.

Devices and methods are provided for applying vacuum near to devices for delivering treatments to tissue adjacent a body cavity, effective to draw adjacent tissue near to such devices and to enhance treatment of the tissue. Body cavities include natural body cavities and cavities remaining after removal of tissue such as cancerous tissue. A device may include an inner balloon assembly with an inflation conduit. A sheath assembly having a fluid-permeable sheath wall may enclose the inner balloon assembly. Vacuum applied to the space between the sheath and the inner balloon is useful to draw tissue into contact with the device, improving treatment effectiveness. Methods for treating tissue with such devices and systems are also provided. Treatments may include providing radioactive material for radiation treatment, providing chemotherapeutic material for chemotherapy, providing thermal treatment, and combinations thereof. Systems may include devices of the invention and a vacuum source.

A flexible, conformable, sensor assembly is provided, including an electrode array especially adapted for stable, long-term recording of EEG signals from a pre-term or neonatal infant in intensive care. A kit or sterile pack includes guidance for placement of the electrodes over a designated area of the infant's brain, an area likely to be injured. The sensor assembly includes a left-side and a right-side flexible strip bearing at least electrodes and optional temperature, motion, and optical sensors provide for the monitoring of an extended range of parameters including aspects of cerebral perfusion and metabolism. Optional impedance measurements provide an indication of neuronal swelling. Stable performance over from three days to about a week is intended so that progress, effects of treatment, and outcome can be considered.

The invention provides a method of distinguishing small RNA from mRNA by contacting a biological isolate with a phosphate reactive reagent having a label moiety under conditions wherein the label moiety is preferentially added to the 5′ phosphate of small RNA over the 5′ cap structure of mRNA and distinguishing the small RNA from the mRNA according to the presence of the label. The invention further provides a method of identifying a plurality of different small RNAs by adding a unique extension sequences to different small RNA sequences and identifying the extended small RNA sequences. Furthermore, the invention provides diagnostic methods for determining presence of a disease or condition such as cancer. Also provided are prognostic methods for determining progression of a disease or condition or for monitoring effectiveness of a treatment for a disease or condition

Implantable osmotic pump devices and systems include multiple osmotic pumps and / or semipermeable membranes to extend the useful life cycle and functionality of the drug delivery system. Use of an implantable system including multiple implantable osmotic pumps allows different drugs to be administered from the same implanted system. One or more of the semipermeable membranes of the system may be initially sealed by an overlying impermeable membrane upon implantation of the system into the patient. When the patient develops a tolerance to a first drug or to a first dose of the first drug, the impermeable membrane may be breached, to expose the underlying semipermeable membrane to the osmotic pressure of the patient at the implant site. This causes the infusion rate to increase, thereby providing the patient with the needed relief and / or other desired therapeutic effect. In the case of a multiple pump system, breaching an impermeable membrane may cause the infusion of a second drug. The second drug may potentiate a therapeutic effect (such as an analgesic effect) of the first drug, as is the case with Sufentanil and Clonidine.

A noninvasive or minimally invasive treatment of cardiac arrhythmia such as supraventricular and ventricular arrhythmias, specifically atrial fibrillation and ventricular tachycardia, by treating the tissue with heat produced by ultrasound, (including High Intensity Focused Ultrasound or HIFU) intended to have a biological and / or therapeutic effect, so as to interrupt or remodel the electrical substrate in the tissue area that supports arrhythmia.

A booster comprising a plenty of microbubbles of a gas in a liquid, e.g. about 4x107 cells / ml of microbubbles of a gas having a diameter of 0.1 to 100 mu m in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.

Spinal disc therapy systems in accordance with the present invention generally include an implant element structured to have a therapeutic effect on a human or animal body when implanted into an intervertebral disc annulus or intervertebral disc nucleus. The implant element may include a biochemically active agent that provides pain relief, inflammation relief or other benefit to the human or animal body. The implant element may be mechanically active or mechanically activatable in being effective in providing a therapeutic effect to the human or animal body when implanted in the intervertebral disc. For example, the implant element may include a mechanically active or mechanically activatable component that radiates wave energy, for example, in the form of electrical or magnetic energy, into the body.

Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such treatments are also provided.

The present invention is directed to a method and apparatus for electrical stimulation of the pancreatico-biliary system. Electrode sets are placed in the pancreatico-biliary system in an arrangement that induce contractions or relaxation of the portion or whole of the pancreatico-biliary system by electrical stimulation of the surrounding tissue, muscles and nerves. The electrical stimulus is applied for periods of varying duration and varying frequency so as to produce the desired therapeutic effect, including inhibiting fat digestion or fat absorption by a patient and inducing satiety in the patient.

This invention describes the use of pharmaceutical compositions, which comprise three components of which at least one is a slow release therapeutic agent. Such useful compositions are applicable for the treatment of humans suffering from diabetic, hypertensive, cardiovascular, hyperlipidemic conditions and their associated disorders thereof. Combination therapy has the advantages of better patient compliance; better therapeutic efficacy coupled with a reduction in the dose for some of the individual therapeutic agent(s) in the combination.

The invention provides a system for restoring organic contaminated soil through in-situ electrical heating. The system comprises an infrastructure technology, an electronic control system, a gas treatment system, a monitoring and data acquisition system and a repairing effect comprehensive assessment system. The infrastructure technology comprises heating well and extraction well construction, ground compaction and insulating layer construction technologies; heating wells are distributed on a contaminated site according to a triangle arrangement principle and a proximity principle, and the extraction well is arranged in the geometric center of the layout of the heating well; the gas treatment system is composed of a pre-cooling adsorption sledge, an extraction sledge and a treatment sledge, and is used for completing gas extraction and treatment and achieving the tail gas discharging requirement; and the repairing effect comprehensive assessment system evaluates the temperature risingeffect of the contaminated soil in the restoring process and the treatment effect of the contaminated soil. According to the system, the technological route is complete, the soil property applicability is wide, the heating temperature can reach 500 DEG C or above, and volatile and difficult-to-volatilize organic contaminant can be treated at the same time.

This invention discloses compositions of chloroquine-coupled active agents such as therapeutic antibodies or insulin, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the drug is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a drug directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing the drug for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and antibody or insulin to their site of action.

The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

The present invention enhances the effectiveness of treatment of support tissue structures. Generally, such tissue structures support organs and hold the organs in their proper position for appropriate functioning. When such tissue structures become weak, hyper-elastic, and / or excessively lengthy, the organs of are no longer supported in their proper position. This often leads to physical manifestations such as incontinence, hernias, and the like. Remedies often involve thermal treatment of the support tissue structures, such as thermally inducted controlled shrinkage, contraction, or stiffening of the support tissue structure. To enhance such thermal treatment and diminish the possibility of undesirable heating and damage to nearby tissue surfaces, vasoconstrictive agents are used.

The present application provides methods and devices for diagnosing and / or predicting the presence, progression and / or treatment effect of a disease characterized by retinal pathological changes in a subject.

A treatment method is disclosed for treating a bodily tissue utilizing one or more steps of removal of material as well as one or more steps of energy delivery in order to effectively treat the bodily tissue. These mechanisms of treatment may beneficially be used to induce separate treatment effects, for example to treat both the symptoms and the underlying cause of a specific pathological condition. In addition, a specific application of the inventive method is described for using the inventive method to treat an intervertebral disc.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition.

A method and apparatus for electrical stimulation of the lower esophageal sphincter (LES) is provided. Electrode sets are placed in the esophagus in an arrangement that induce contractions of the LES by electrical stimulation of the surrounding tissue and nerves. The electrical stimulus is applied by a pulse generator for periods of varying duration and varying frequency so as to produce the desired contractions. The treatment may be short-term or may continue throughout the life of the patient in order to achieve the desired therapeutic effect. The stimulating electrode sets can be used either alone or in conjunction with electrodes that sense esophageal peristalsis. The electrode sets can be placed endoscopically, surgically or radiologically.

A method for delivering a polynucleotide to cardiac tissue, including substantially isolating the coronary venous circulation from systemic circulation, and introducing a polynucleotide into the isolated coronary venous circulation to effect localized transfection of cardiac tissue. The polynucleotide advantageously produces a therapeutic effect, such as increasing or decreasing the expression level of a protein in the cardiac tissue.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

Embodiments described herein provide a skin penetrating device and method for the subcutaneous delivery of therapeutic agents in solid form. One embodiment provides such a device comprising an elongated shaft having proximal and distal ends and a skin penetrating element detachably coupled to the shaft. At least a portion of the penetrating element is fabricated from a solid form therapeutic agent composition that dissolves in body tissue and is absorbed into the blood stream so as to produce a therapeutic effect. The penetrating element has shape for penetrating and lodging beneath the skin when inserted through the skin by force applied from the shaft. The penetrating element is configured to detach from the shaft when the shaft is pulled away from the skin so as to leave the element in place beneath the skin where it is absorbed by body tissue and the therapeutic agent is released.

The present disclosure relates to novel dosage forms, drug delivery regimens, methods and pharmaceutical compositions which optimize the therapeutic effects of active therapeutic substances through the application of the concept of uneven dosing.

The present invention relates generally to efficient delivery of viral vectors to cells of the CNS, particularly useful in the treatment of neurodegenerative disorders and motor neuron diseases. The invention involves selecting a first population and a second population of synaptically connected neurons, wherein a therapeutic polypeptide is to be expressed in said second population of neurons; and administering rAAV virions comprising a therapeutic gene to said first subpopulation of neurons of said subject such that the rAAV virions are transported across a synapse between synaptically connected neurons. In another aspect the present invention also comprises the use of rAAV virions carrying a transgene in the preparation of a medicament for the treatment of a disease in a subject, wherein a first population and a second population of synaptically connected neurons are selected and a therapeutic polypeptide is to be expressed in said second population of neurons; and a medicament comprising recombinant adeno-associated virus (rAAV) virions is delivered to said first population of neurons of the subject, wherein said virions comprise a nucleic acid sequence that is expressible in transduced cells to provide a therapeutic effect in the subject, and wherein said rAAV virions are capable of transducing a synaptically connected neurons.

The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Methods of enhancing stem cell therapy through the administration of low level light energy are provided in several embodiments. Some embodiments comprise irradiating stem cells before or after implantation at a target tissue having loss of function due to damage or disease, with a resultant increase in the efficacy of the cell therapy. In some embodiments, light energy enhances one or more of the viability, proliferation, migration or engraftment of the stem cells, thereby enhancing the therapeutic effects of the irradiated cells during cell therapy.

A heat vest system that includes a garment wearable by the user having strategically located vibration and heating elements which is worn by the user such that the heating and vibration elements are correctly positioned for a therapeutic effect. To increase the therapeutic effect, the system includes a control device in connection with the vibration and heating elements of the garment which allows the user to separately adjust the heat and vibration generated by each of the heating and vibration elements.